Kamin, F
Rommer, P S
Abu-Mugheisib, M
Koehler, W
Hoffmann, F
Winkelmann, A
Benecke, R
Zettl, U K
Article History
Received: 3 March 2014
Revised: 10 July 2014
Accepted: 1 August 2014
First Online: 16 September 2014
Competing interests
: PSR served as consultant to Bayer Pharma AG and received speaker honorary from Shire. He received travel support from Biogen Idec. He has recently entered employment with Novartis. WK received travel support, research grant and speaker fees from Biogen Idec, Bayer Healthcare, Merck-Serono, Novartis and Teva. FH received travel support from Bayer Healthcare and Biogen Idec; received research grants from Allergan, Bayer Healthcare, Biogen Idec, Genzyme, Ipsen, Merz, Novartis, Teva and UCB; received speaker or consultant fees from Allergan, Bayer Healthcare, Biogen Idec, Genzyme, Ipsen, Merz, Novartis and Teva. AW received travel support from Novartis and Genzyme; received speaker and consultant fees from Merck-Serono and Genzyme. UKZ received speaker fees from Almirall,Bayer Healthcare, Biogen Idec, Genzyme, Merck-Serono, Novartis, Sanofi and Teva. The remaining authors declare no conflict of interest.